NVCR · XBRL financial data

NovoCure financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (NVCR's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Revenue	134*	139	150	155	161*	155	159	167	174*	174	184	193
Cost of revenue	33*	34	35	35	33*	39	41	45	42*	39	41	45
Gross profit	101*	105	116	120	128*	116	117	122	132*	135	142	149
Research and development	54*	52	55	52	51*	54	56	54	61*	58	51	58
General and administrative	39*	40	38	40	72*	45	44	46	43*	86	40	44
Total operating expenses	153*	146	149	152	191*	154	157	158	173*	203	153	155
Operating income (loss)	(52)*	(42)	(34)	(32)	(63)*	(38)	(40)	(36)	(40)*	(67)	(11)	(6)
Interest income	year only	—	—	—	year only	—	—	—	year only	—	—	—
Interest expense	year only	—	—	—	year only	—	—	—	year only	—	—	—
Income tax expense (benefit)	9*	7	11	9	11*	4	5	7	(16)*	2	3	3
Net income (loss)	(47)*	(39)	(33)	(31)	(66)*	(34)	(40)	(37)	(24)*	(71)	(16)	(10)
Earnings per share, basic USD per share	(0.44)*	(0.36)	(0.31)	(0.28)	(0.61)*	(0.31)	(0.36)	(0.33)	(0.22)*	(0.62)	(0.13)	(0.09)
Earnings per share, diluted USD per share	(0.44)*	(0.36)	(0.31)	(0.28)	(0.61)*	(0.31)	(0.36)	(0.33)	(0.22)*	(0.62)	(0.13)	(0.09)
Weighted average shares, basic millions of shares	107*	107	108	108	108*	110	112	112	112*	114	116	117
Weighted average shares, diluted millions of shares	107*	107	108	108	108*	110	112	112	112*	114	116	117

Fiscal quarters (NVCR's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Cash and cash equivalents	241	454	165	185	164	127	150	342	94	88	94	97
Accounts receivable	61	65	65	67	74	85	90	85	89	93	99	108
Inventory	38	42	40	39	35	39	40	39	41	43	42	41
Total current assets	1,034	1,003	1,093	1,095	1,107	1,089	1,083	1,200	647	632	639	674
Property and equipment, net	51	59	66	73	78	80	80	80	78	76	75	73
Right-of-use asset	35	33	29	28	27	49	48	48	47	45	44	43
Total assets	1,146	1,121	1,212	1,222	1,241	1,249	1,246	1,361	804	788	795	829
Current portion of long-term debt	—	—	—	—	—	—	—	—	0	—	—	25
Total current liabilities	179	160	169	735	756	743	750	776	223	218	221	271
Long-term debt	569	570	—	—	97	—	—	—	195	—	—	—
Lease liability, non-current	27	26	22	21	20	40	43	43	42	39	38	35
Total liabilities	784	762	850	861	881	887	896	1,020	464	457	457	478
Accumulated deficit	(986)	(1,024)	(1,058)	(1,088)	(1,154)	(1,188)	(1,229)	(1,266)	(1,290)	(1,361)	(1,377)	(1,388)
Total stockholders' equity	362	359	362	361	360	362	349	341	340	331	338	351
Total liabilities and equity	1,146	1,121	1,212	1,222	1,241	1,249	1,246	1,361	804	788	795	829
Common shares outstanding (cover page) millions of shares	107	108	108	108	110	111	112	112	114	116	116	117

Fiscal quarters (NVCR's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Net income (loss)	(47)*	(39)	(33)	(31)	(66)*	(34)	(40)	(37)	(24)*	(71)	(16)	(10)
Stock-based compensation	17*	34	32	31	63*	30	26	29	20*	63	17	17
Net cash from operating activities	(15)*	(32)	(2)	10	(3)*	(36)	(16)	21	(18)*	(14)	8	23
Purchases of property and equipment	7*	12	11	11	9*	11	5	6	5*	5	7	7
Net cash from investing activities	99*	246	(374)	10	(22)*	(6)	36	71	336*	8	(6)	(23)
Proceeds from issuing common stock	2*	0	2	0	2*	0	2	0	2*	0	2	0
Proceeds from long-term debt	0*	0	97	0	0*	0	0	100	0*	0	0	0
Repayments of long-term debt	0*	0	13	0	0*	0	0	0	561*	0	0	0
Net cash from financing activities	2*	0	87	0	3*	5	2	101	(559)*	(0)	5	4
Net change in cash	86*	215	(289)	21	(23)*	(37)	23	193	(241)*	(6)	6	3

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
NovoCure	97	193	23	116.9M	—	Q3 FY26 10-QSep 30, 2026
Establishment Labs Holdings	71	68	(17)*	29.8M	4.3 quarters	Q2 FY26 10-QJun 30, 2026
Integra Lifesciences Holdings	252	411	96*	77.8M	—	Q3 FY26 10-QSep 30, 2026
Biolife Solutions	24	not reported	6.3*	48.9M	—	Q2 FY26 10-QJun 30, 2026
CONMED	48	336	49*	29.8M	—	Q3 FY26 10-QSep 30, 2026
SI-BONE	35	56	5.9*	45.1M	—	Q3 FY26 10-QSep 30, 2026
Alphatec Holdings	80	221	19*	155.1M	—	Q3 FY26 10-QSep 30, 2026
Tandem Diabetes Care	63	255	(35)*	69.6M	13.2 quarters	Q2 FY26 10-QJun 30, 2026
Embecta	215	272	42*	56.7M	—	Q3 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.